retatrutide safety clinical trials A new trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes retatrutide safety profile clinical trials

GLP-1 Dosage Chart by Medication Understanding how dosage increases over time is crucial to managing side effects and achieving results

Eating disorders: recognition and treatment

suis culture

Among other things, the authors found that greater postprandial glucose dips were associated with a shorter time to the next meal (which suggests greater hunger) and greater energy intake within 34 h after a meal (or even within 24 h) and showed that glucose dips 23 h after a meal were a better predictor of subjective feelings of hunger (and subsequent energy intake) than peak (and cumulative) glucose levels within 2 h after a meal